J.MelhornS
[DOI] [PMC free article] [PubMed] [Google Scholar] [16].Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torne CW, Ryan DH, Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, N Engl J Med (2023)
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
Diabetes 49(4), 611617
Therefore, the development of an oral delivery strategy for peptide GLP-1R agonists is expected to reduce these adverse effects and improve patient compliance and quality of life (Borner et al., 2020
PA, AMPK inhibitor compound C and GLP-1R antagonist exendin (939) were purchased from Sigma (St